FDA accepts Emergent BioSolutions’ anthrax vaccine candidate for review

FDA accepts Emergent BioSolutions’ anthrax vaccine candidate for review

Source: 
Pharmaceutical Business Review
snippet: 

The US Food and Drug Administration (FDA) has agreed to review Emergent BioSolutions’ Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).